Use of markers in defining urothelial premalignant and malignant conditions

Scandinavian Journal of Urology and Nephrology, Supplement

Volumn 34, Issue 205, 2000, Pages 94-104

  Grossman, H Barton ^a,e   Schmitz Dräger, Bernd ^b   Fradet, Yves ^c   Tribukait, Bernhard ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b Euromed Clinic   (Germany)

^c UNIVERSITÉ LAVAL   (Canada)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Malignancy; Markers; Premalignancy; Urothelium

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19 FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 19A211; MONOCLONAL ANTIBODY DD23; MONOCLONAL ANTIBODY M344; UNCLASSIFIED DRUG; TUMOR MARKER;

BLADDER CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CARCINOMA IN SITU; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE MARKER; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; PRECANCER; PREDICTION; PRIORITY JOURNAL; SAFETY; VALIDATION PROCESS; BLADDER; BLADDER TUMOR; CELL TRANSFORMATION; CLINICAL TRIAL; DISEASE COURSE; PATHOLOGY; PREDICTION AND FORECASTING; REVIEW; TRANSITIONAL CELL CARCINOMA;

CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; DISEASE PROGRESSION; HUMANS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0034353138     PISSN: 03008886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Harnden P, Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 1999; 353: 974-7.
2. Koss LG, Tiamson EM, Robbins MA. Mapping cancerous and precancerous bladder changes. A study of the urothelium in ten surgically removed bladders. JAMA 1974; 227: 281-6.
3. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999; 23: 443-7.
4. Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Usui T, et al. A mapping of histology and cell proliferation in human bladder cancer: an immunohistochemical study. Hiroshima J Med Sci 1995; 44: 93-7.
5. Lee E, Schwaibold H, Fradet Y, Huland E, Huland H. Tumor-associated antigens in normal mucosa of patients with superficial transitional cell carcinoma of the bladder. J Urol 1997; 157: 1070-3.
6. Rao JY, Hemstreet III GP, Hurst RE, Bonner RB, Jones PL, Min KW, et al. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sci USA 1993; 90: 8287-91.
7. Celis JE, Celis P, Ostergaard M, Basse B, Lauridsen JB, Ratz G, et al. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res 1999; 59: 3003-9.
8. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999; 154: 721-7.
9. Hemstreet III GP, Rao J, Hurst RE, Bonner RB, Waliszewski P, Grossman HB, et al. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials. J Cell Biochem Suppl 1996; 25: 197-204.
10. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999; 162: 53-7.
11. Fradet Y, Lafleur L, LaRue H. Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder. J Cell Biochem Suppl 1992; 161: 85-92.
12. Fradet Y, Lockhart C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt. Can J Urol 1997; 4: 400-5.
13. Grossman HB, Washington Jr RW, Carey TE, Liebert M. Alterations in antigen expression in superficial bladder cancer. J Cell Biochem Suppl 1992; 161: 63-8.
14. Bonner RB, Liebert M, Hurst RE, Grossman HB, Bane BL, Hemstreet III GP. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Cancer Epidemiol Biomarkers Prev 1996; 5: 971-8.
15. Senga Y, Kimura G, Hattori T, Yoshida K. Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer. Urology 1996; 48: 703-10.
16. Pariente JL, Bordenave L, Michel P, Latapie MJ, Ducassou D, LeGuillou M. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 1997; 158: 338-41.
17. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Espasa A, Chinchilla V, et al. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder. J Urol 1999; 161: 1110-5.
18. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 1999; 162: 1951-6.